(a).
Scenarios | Total cost ($) | Total effectiveness (QALY) | Incremental costs ($) | Incremental effectiveness (QALY) | ICER ($/QALY) |
---|---|---|---|---|---|
Cochrane (base-case) | |||||
AZA | 54,249.98 | 1.6367 | |||
MMF | 71,861.21 | 1.6434 | 17,611.23 | 0.0067 | 2,630,591.76 |
Subgroups | |||||
ALMS | |||||
AZA | 55,959.12 | 1.6125 | |||
MMF | 72,619.05 | 1.6363 | 16,659.92 | 0.0238 | 700,001.12 |
MAINTAIN | |||||
AZA | 54,527.62 | 1.6318 | |||
MMF | 72,511.65 | 1.6148 | 17,984.04 | −0.0170 | Dominated |
QALY: quality-adjusted life-years; AZA: azathioprine; MMF: mycophenolate mofetil.